Afterword: The Paris System for Reporting Urinary Cytology
|
|
- Agatha McCarthy
- 5 years ago
- Views:
Transcription
1 Afterword: The Paris System for Reporting Urinary Cytology Dorothy L. Rosenthal, Eva M. Wojcik, and Daniel F.I. Kurtycz The primary goal of The Paris System Working Group was standardizing the terminology for reporting urinary cytology based upon histopathology and clinical outcomes. Soon after the initiation of this project, we realized that much of our knowledge base was anecdotal, poorly defined, inadequately studied, or uninvestigated. Therefore, the Working Group depended not only upon the extant medical literature but also considered the data from newly initiated and completed studies that were needed to reach the goal. From the initial meeting in Paris, we have agreed that detection of High Grade Urothelial Carcinoma is the ultimate goal of urine cytology. Therefore, the entire system was built based on this principle. As a consequence, one of our goals has been to define the risk of HGUC for each diagnostic category based upon tissue confirmation and clinical outcome. This goal, however, can only be accomplished if the standardized terminology is used for defining risk related to the initial diagnostic categories. As such, prospective studies will have to be done to define those risks. The decision to emphasize HGUC was based most importantly on clinical significance but also on pathogenetic bases of urothelial carcinoma. Although we have presented these pathways in a very simplistic way, we understand that a significant body of work has yet to be done to confirm that low-grade urothelial neoplasms are not carcinomas. As a remedy for this general ignorance, we decided to divide our knowledge of the pathogenesis of Bladder Cancer into two major categories: those causes of cellular neoplastic changes that have been verified by molecular and genetic tests, and those that are still theories or totally unexplored. This First Edition of The Paris System for Reporting Urinary Cytology (2015) has covered the morphology of cytologic changes from benign to malignant, and has modestly stated what we believe to be generally accepted causes of these changes. Many of the ancillary tests are still in the investigative phase of their development (see Chap. 9 ) and are in serious need of large clinical trials to validate their clinical reliability and reproducibility among individuals and laboratories. Springer International Publishing Switzerland 2016 D.L. Rosenthal et al. (eds.), The Paris System for Reporting Urinary Cytology, DOI /
2 154 D.L. Rosenthal et al. In anticipation of The Second Edition, the editors, DR, EW, and DK, have asked the Corresponding Authors of the Working Groups to provide us with a Wish List, i.e., those aspects relative to the topic of their chapter that are in immediate need of investigation. The major purpose of this list, summarized as an appendix to this Afterword, is to stimulate seminal research by medical scientists. We also hope that funding agencies, whether governmental, philanthropic or private industry, will step forward and turn this Grass Roots effort into a major force in combatting Bladder Cancer. As the world s population ages, bladder cancer will become more of a financial burden than it already is, worthy of effective methods of prevention, and early noninvasive detection methods resulting in minimal procedures for effective cures. Future Clinical and Research Needs for All Diagnostic Categories of The Paris System for Reporting Urinary Cytology General essentials to assure the longevity of The Paris System 1. Determine the reporting rates of all categories after proper usage of the criteria has occurred for a significant period of time. 2. Perform outcome and interobserver reproducibility studies with the updated criteria. 3. Relate risk for the development of HGUC to the cytologic categories. 4. Establish clear-cut management guidelines based upon outcomes and with input from Urologic Surgeons and acceptance of patients. 5. Consider whether subsequent urothelial tumors are a recurrence of the initial tumor or a new lesion. Chapter 1: Pathogenesis 1. Conduct further molecular studies to confirm or disprove that hyperplastic and dysplastic pathways are separate in the pathogenesis of urothelial neoplasms. 2. Further evaluate the concept that low grade urothelial neoplasms (LGUNs) are not carcinomas. Chapter 2: Specimen Adequacy 1. Define essential variables, e.g., optimal minimum and maximum volume of voided urines, cellularity necessary for diagnosis of HGUC, preservation of cellular integrity dependent upon length of time between collection and processing. 2. Establish when the term inadequate is appropriate, and the clinical implications. Chapter 3: Negative for HGUC (NHGUC) 1. Catalogue outcomes of all entities included within the NHGUC category. 2. Explore whether any of the benign entities, especially Polyoma virus and calculi, have a causal relationship with urothelial cancers.
3 Afterword: The Paris System for Reporting Urinary Cytology 155 Chapter 4: Atypical Urothelial Cells (AUC) 1. Construct studies to refine criteria and meaningfully reduce the size of the AUC category. 2. Compare use of the category among laboratories of various sizes and risk levels of patients. Chapter 5: Suspicious for HGUC (SHGUC) 1. Define the cytological categories of suspicious for HGUC and positive for HGUC in terms of their association with subsequent histological HGUC diagnoses to determine whether they should remain separate categories. 2. Establish management guidelines for a suspicious diagnosis based on the results of future large studies. Chapter 6: HGUC 1. Define the specificity and sensitivity of HGUC cytology for detecting HGUC on biopsy, depending upon the type of cytologic sample obtained. 2. Design large prospective studies to establish risk of recurrence and invasion based upon grade predicted by cytologic diagnosis. Chapter 7: LGUN 1. Construct studies that are adequately powered to achieve statistical significance in order to establish the clinical utility of the LGUN category. 2. Decide whether any lesions within the LGUN category are truly carcinomas, i.e., capable of invading and metastasizing, and whether these lesions can progress from LGUC to HGUC. Chapter 8: Non-urothelial 1. Evaluate clinical data from major academic centers to assess the success of morphology and immunohistochemistry for cytological detection of non-urothelial malignancies of the urinary tract. 2. Investigate application of innovative molecular and genetic tests to aid in the identification of sources of non-urothelial cancers of the urinary tract as well as determine the cell of origin in primary non-urothelial tumors. Chapter 9: Ancillary Tests 1. Prospectively compare the performance of novel tests on the sensitivity and negative predictive value of AUC and SHGUC categories. 2. Determine whether surveillance guidelines can be changed using currently approved ancillary tests (e.g., U-FISH and ucyt) for patients with urothelial carcinoma depending on individual risk factors. 3. Establish the cost-effectiveness of ancillary testing across different countries and health care systems.
4 156 D.L. Rosenthal et al. Chapter 10: Preparation 1. Determine whether time, temperature, and chemical composition of urine impact collection and processing. 2. Establish evidence-based recommendations for collecting urine specimens (e.g., voided early a.m. vs. discard-hydrate-void; voided vs. catheterized vs. washing). Chapter 11: Clinical Management 1. Explore new technologies to improve the accuracy of cystoscopy, such as fluorescence- assisted cystoscopy, narrow band imaging, among others, that have been introduced or will be coming down the pipeline. 2. Perform prospective clinical trials to see how these tests can be integrated with cytology to enhance its performance.
5 Index A Adenocarcinoma (AdCa), 93, 108 Adequacy, 5 algorithm, 6 7 of instrumented urinary tract cytology specimens, 9 10 optimal category, 10 volume, 7 9 Ancillary testing, 115, 116, 130 Angiosarcomas, 104 Atypia, 39, 47, 51, 55 AUC, 3, 119, 120 definition, 40 management of, 145 rate and risk, urinary cytology, Atypical urothelial cells (AUC), 3, 119, 120 B Bacillus Calmette-Guerin (BCG) reaction, 14, 30, 31, 147 Benign conditions, 145 Benign urothelial, squamous and glandular cells, 14 Benign urothelial tissue fragments (BUTF), 14, in instrumented urine, 23 in voided urine, Biomarkers, 129 Bladder diversion urine, 33 BTA, C Chemotherapy, 31 Chromosome enumeration probes (CEP), 116 Computerized tomography (CT) urography, 146 Cystoscopy, Cytocentrifugation, 140 Cytology, 1 Cytomorphological findings, 137 Cytopreparation, 137, 138 E Enteric epithelial cells, 14 Epithelial tumors, Extrapulmonary small cell carcinoma (SmCC), 98 F Flat low-grade urothelial dysplasia, 83 Fluorescence in situ hybridization (FISH), 117, 119 G Glandular cells, H High-grade urothelial carcinoma (HGUC), 13, 25, 33, 49, 61, 65 67, 69, 70 criteria, 68 cytologic definition, 64 Springer International Publishing Switzerland 2016 D.L. Rosenthal et al. (eds.), The Paris System for Reporting Urinary Cytology, DOI /
6 158 High-grade urothelial carcinoma (HGUC) (cont.) cytomorphologic characteristics of, 63 definition, 49 with glandular differentiation, 67 histologic definition, 63 with squamous differentiation, 65 Hyperchromasia, 55 I Immunocyt, Immunotherapy, 30 Intravesical immunotherapy, 145, 147, 148 L Leiomyosarcoma, 102 Low-grade papillary urothelial carcinoma (LGPUC), 75, 77, 80, 81, 83 Low-grade papillary urothelial neoplasm (LGPUN), 77, 83 Low-grade urothelial neoplasia (LGUN) criteria, 77 cytologic criteria, 77 management, 147 positive, 78 M Markers tumor, 127 urinary, 115, 129 Melanoma, 104 Metastasis, 87 hematogenous, 97 urinary bladder, 88 Micropapillary tumors, 148 Millipore filtration, 138, 140 Mitomycin C, 147 N Negative for high-grade urothelial carcinoma (NHGUC), 3, 13 components, definition, 14 management of negative, 143 Nephrolithiasis three-dimensional urothelial tissue fragments, 25 urothelium, 25 Neuroendocrine (NE) tumors, 148 NMP22, 116, Non-epithelial tumors, Non-urothelial carcinoma (non-uc), 87 Non-urothelial tumors, 148 P Papillary urothelial neoplasm of low malignant potential (PUNLMP), 75, 76, 80, 83 Paris System for Reporting Urinary Cytology (The Paris System), 116 Pathogenesis, 1 Polyoma (BK) virus, 14, 28, 30 Post-cystectomy treatment changes, 14, 34 Preliminary microscopic specimen assessment, 138 Primary adenocarcinomas, 148 Primary non-urothelial tumors, 87 R Radiation-induced cytomorphologic changes, 30 Radical cystectomy, 148, 145, 148 Reactive urothelial cells, 14, 25, 28 Reporting system, 1 S Sarcomatoid carcinoma, 104 Seminal vesicle cells, 32 Severe atypia, 49 Squamous cell carcinoma (SqCC), 88, 148 SurePath, 140, 141 Suspicious for high-grade urothelial carcinoma (SHGUC), 3, 40, 49, 60, 146 T ThinPrep, 141 Transurethral resection, Tumor-like lesions, U U-FISH test, Unsatisfactory specimens, 149 Upper tract urothelial carcinoma, 146, 147 Urethral recurrences, 144, 147 Urinary bladder, 75 mesenchymal tumor, 102 metastases, 88, 107 primary AdCa, 95 primary carcinoid tumors, 98 Index
7 Index 159 primary LCNEC, 102 primary paragangliomas, 112 spindle cell lesions, 102 Urine collection, 142 Urine cytology, 5, 116, 126, 145 HGUC definition, 64 positive, 62 PUNLMP, 80 reporting system, Urine processing, 138, 140 Urolithiasis, 25 Urothelial atypia, 46, 47 Urothelial carcinoma (UC), 6, 115 detection, 1 dysplasia pathway, 2 low-grade papillary, 2 neoplastic transformation, 1 3 NHGUC, 3 pathogenesis, 1 SHGUC, 3 Urothelial cells, 23 Urothelial papilloma, 75 77, 80 Urothelium acute bacterial infections, nephrolithiasis, 25 viral cytopathic effects, 28 UroVysion, 116 in atypical urinary cytology, cost-effectiveness of, 123 imaging and automation of, pitfalls in, 125
Toyonori Tsuzuki MD, PhD Professor and Chair Department of Surgical Pathology Aichi Medical University Hospital
29th European Congress of Pathology (ECP 2017) Amsterdam RAI. The Paris System for Reporting Urinary Cytology: The Concept and Management Toyonori Tsuzuki MD, PhD Professor and Chair Aichi Medical University
More informationRationale of The Paris System for Reporting Urinary Cytopathology: The NEW paradigm
Rationale of The Paris System for Reporting Urinary Cytopathology: The NEW paradigm Eva M. Wojcik, MD Professor and Chair of Pathology Professor of Urology Loyola University, Chicago, Il Why to standardize
More informationThe application of cytology in urological diseases
Voided urine cytology The application of cytology in urological diseases Dr Ashish Chandra FRCPath DipRCPath (Cytol) Guy s & St Thomas NHSfT London Detection of high grade urothelial carcinoma Monitoring
More informationUrinary Cytology. Spasenija Savic Prince, MD Pathology, University Hospital Basel, Switzerland
Urinary Cytology Spasenija Savic Prince, MD Pathology, University Hospital Basel, Switzerland Outline Pre-analytics The Paris System (TPS): Background Diagnostic categories Morphologic criteria for each
More informationUrinary Cytology. Spasenija Savic Prince Pathology, University Hospital Basel, Switzerland
Urinary Cytology Spasenija Savic Prince Pathology, University Hospital Basel, Switzerland Outline Pre-analytics The Paris System (TPS): Background Diagnostic categories Morphologic criteria for each category
More informationApplication of Urovision FISH testing for diagnosis of bladder cancer
Application of Urovision FISH testing for diagnosis of bladder cancer Eva M. Wojcik, MD Chair and Professor of Pathology and Urology Loyola University, Chicago, USA Bladder cancer - current status ~ 76,900
More informationIndex 179. Genital tract contaminants, 17, 20, 22, 150 papilloma virus-infected cells, 47 squamous cells, sources of, 7
Index Accuracy of urinary cytology, 166 Acute inflammatory cells, 38 catheter sample, 39 herpes simplex infections, 44 carcinomas, 104, 105 non-viral inclusions, 52, 53 voided urine, 17 Adenocarcinoma
More informationGUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER
GUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER (Limited text update December 21) M. Babjuk, W. Oosterlinck, R. Sylvester, E. Kaasinen, A. Böhle, J. Palou, M. Rouprêt Eur Urol 211 Apr;59(4):584-94 Introduction
More informationMUSCLE-INVASIVE AND METASTATIC BLADDER CANCER
MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER (Text update March 2008) A. Stenzl (chairman), N.C. Cowan, M. De Santis, G. Jakse, M. Kuczyk, A.S. Merseburger, M.J. Ribal, A. Sherif, J.A. Witjes Introduction
More informationGuidelines for the Management of Bladder Cancer West Midlands Expert Advisory Group for Urological Cancer
Guidelines for the Management of Bladder Cancer West Midlands Expert Advisory Group for Urological Cancer West Midlands Clinical Networks and Clinical Senate Coversheet for Network Expert Advisory Group
More informationCarcinoma of the Urinary Bladder Histopathology
Carcinoma of the Urinary Bladder Histopathology Reporting Proforma (Radical & Partial Cystectomy, Cystoprostatectomy) Includes the International Collaboration on Cancer reporting dataset denoted by * Family
More informationThe pathology of bladder cancer
1 The pathology of bladder cancer Charles Jameson Introduction Carcinoma of the bladder is the seventh most common cancer worldwide [1]. It comprises 3.2% of all cancers, with an estimated 260 000 new
More informationCarcinoma of the Renal Pelvis and Ureter Histopathology
Carcinoma of the Renal Pelvis and Ureter Histopathology Reporting Proforma (NEPHROURETERECTOMY AND URETERECTOMY) Includes the International Collaboration on Cancer reporting dataset denoted by * Family
More informationKidney, Bladder and Prostate Neoplasia. David Bingham MD
Kidney, Bladder and Prostate Neoplasia David Bingham MD typical malignant cytology of bladder washings 1 benign 2 malignant typical malignant cytology of bladder washings b Bladder tumor Non invasive papillary
More informationMUSCLE - INVASIVE AND METASTATIC BLADDER CANCER
10 MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER Recommendations from the EAU Working Party on Muscle Invasive and Metastatic Bladder Cancer G. Jakse (chairman), F. Algaba, S. Fossa, A. Stenzl, C. Sternberg
More informationURINE CYTOLOGY. Richard Doughty Avd for patologi Ahus
URINE CYTOLOGY Richard Doughty Avd for patologi Ahus The main purpose of urine cytology is To detect High Grade Urothelial Carcinoma Outline Urine the basics A little on the history of claasification
More informationImpact of Implementing the Paris System for Reporting Urine Cytology in the Performance of Urine Cytology A Correlative Study of 124 Cases
Impact of Implementing the Paris System for Reporting Urine Cytology in the Performance of Urine Cytology A Correlative Study of 124 Cases Muhannad Hassan, MD, 1 Sharaddha Solanki, MSc, 2 Wassim Kassouf,
More informationCorporate Medical Policy
Corporate Medical Policy Urinary Tumor Markers for Bladder Cancer File Name: Origination: Last CAP Review: Next CAP Review: Last Review: urinary_tumor_markers_for_bladder_cancer 5/2011 11/2017 11/2018
More informationEAU GUIDELINES ON NON-MUSCLE INVASIVE (TaT1, CIS) BLADDER CANCER
EU GUIDELINES ON NON-MUSLE INVSIVE (TaT1, IS) LDDER NER (Limited text update March 2017) M. abjuk (hair), M. urger (Vice-hair), E. ompérat, P. Gontero,.H. Mostafid, J. Palou,.W.G. van Rhijn, M. Rouprêt,
More informationA patient with recurrent bladder cancer presents with the following history:
MP/H Quiz A patient with recurrent bladder cancer presents with the following history: 9/23/06 TURB 1/12/07 TURB 4/1/07 TURB 7/12/07 TURB 11/14/07 Non-invasive papillary transitional cell carcinoma from
More informationBLADDER CANCER: PATIENT INFORMATION
BLADDER CANCER: PATIENT INFORMATION The bladder is the balloon like organ located in the pelvis that stores and empties urine. Urine is produced by the kidneys, is conducted to the bladder by the ureters,
More informationJoseph H. Williams, MD Idaho Urologic Institute St. Alphonsus Regional Medical Center September 22, 2016
BLADDER CANCER Joseph H. Williams, MD Idaho Urologic Institute St. Alphonsus Regional Medical Center September 22, 2016 BLADDER CANCER = UROTHELIAL CANCER Antiquated term is Transitional Cell Carcinoma
More informationMEDICAL POLICY SUBJECT: URINARY TUMOR MARKERS FOR BLADDER CANCER. POLICY NUMBER: CATEGORY: Technology Assessment
MEDICAL POLICY SUBJECT: URINARY TUMOR MARKERS FOR PAGE: 1 OF: 5 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product, including
More informationGuidelines on Non-muscle invasive Bladder Cancer (TaT1 and CIS)
Guidelines on Non-muscle invasive Bladder Cancer (TaT1 and CIS) M. Babjuk, W. Oosterlinck, R. Sylvester, E. Kaasinen, A. Böhle, J. Palou, M. Rouprêt European Association of Urology 2011 TABLE OF CONTENTS
More informationAmerican Society of Cytopathology Core Curriculum in Molecular Biology
American Society of Cytopathology Core Curriculum in Molecular Biology American Society of Cytopathology Core Curriculum in Molecular Biology Chapter 6 Fluorescence in situ Hybridization (FISH) Principles
More informationCosting report: Bladder cancer
Putting NICE guidance into practice Costing report: Bladder cancer Implementing the NICE guideline on bladder cancer (NG2) Published: February 2015 Updated September 2015 to update the unit cost of transurethral
More informationBladder cancer (BC) is the fifth most commonly diagnosed malignancy in the United
1 Chapter 1: Background 1.1 Bladder Cancer Incidence and Etiology Bladder cancer (BC) is the fifth most commonly diagnosed malignancy in the United States, with more than 70,000 new cases and more than
More informationDiagnosis & Treatment of Non- Muscle Invasive Bladder Cancer: AUA/SUO Guidelines
Diagnosis & Treatment of Non- Muscle Invasive Bladder Cancer: AUA/SUO Guidelines Sam S. Chang, MD, MBA Patricia & Rodes Hart Chair Professor of Urologic Surgery & Oncology Vanderbilt University Medical
More informationBLADDER CANCER EPIDEMIOLOGY
BLADDER CANCER WHAT IS NEW AND CLINICALLY RELEVANT Canadian Geese - Geist Reservoir (my backyard), Indianapolis, USA BLADDER CANCER EPIDEMIOLOGY Urinary bladder 17,960 2% Urinary bladder 4,390 1.6% Siegel
More informationUrinary Bladder: WHO Classification and AJCC Staging Update 2017
Urinary Bladder: WHO Classification and AJCC Staging Update 2017 Houston Society of Clinical Pathologists 58 th Annual Spring Symposium Houston, TX April 8, 2017 Jesse K. McKenney, MD Classification
More informationUrinary Biomarkers for Cancer Screening, Diagnosis, and Surveillance
Urinary Biomarkers for Cancer Screening, Diagnosis, and Surveillance Policy Number: 2.04.07 Last Review: 12/2018 Origination: 12/2016 Next Review: 6/2019 Policy Blue Cross and Blue Shield of Kansas City
More informationEAU Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and CIS)
EAU Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and CIS) M. Babjuk (Chair), M. Burger (Vice-Chair), E. Compérat, P. Gontero, A.H. Mostafid, J. Palou, B.W.G. van Rhijn, M. Rouprêt, S.F. Shariat,
More informationEffective Health Care Program
Comparative Effectiveness Review Number 153 Effective Health Care Program Emerging Approaches to Diagnosis and Treatment of Non Muscle-Invasive Bladder Cancer Executive Summary Background Bladder cancer
More informationThe innovative aspect is that it detects bladder cancer based on the novel biomarker, minichromosome maintenance complex component 5 (MCM5).
pat hways ADXBLADDER for detecting bladder cancer Medtech innovation briefing Published: 12 April 2019 nice.org.uk/guidance/mib180 Summary The technology described in this briefing is ADXBLADDER. It is
More informationNMIBC. Piotr Jarzemski. Department of Urology Jan Biziel University Hospital Bydgoszcz, Poland
NMIBC Piotr Jarzemski Department of Urology Jan Biziel University Hospital Bydgoszcz, Poland 71 year old male patient was admitted to the Department of Urology First TURBT - 2 months prior to the hospitalisation.
More informationUrinary Bladder, Ureter, and Renal Pelvis
Urinary Bladder, Ureter, and Renal Pelvis Protocol applies to all carcinomas of the urinary bladder, ureter, and renal pelvis. Protocol revision date: January 2005 Based on AJCC/UICC TNM, 6th edition Procedures
More informationMEDitorial March Bladder Cancer
MEDitorial March 2010 Bladder Cancer Last month, my article addressed the issue of blood in the urine ( hematuria ). A concerning cause of hematuria is bladder cancer, a variably malignant tumor starting
More informationCombining Color and Morphology Improves Identification of Low-Grade Urothelial Cancer Cells
Combining Color and Morphology Improves Identification of Low-Grade Urothelial Cancer Cells Alexander Shtabsky 1, Sylvia Lew 2, Ronny Rona 3, Noa Davis 4, Yoram Mor 5, Uri Lindner 6, Ofer Nativ 7, Ofer
More informationTitle: Concurrence of villous adenoma and non-muscle invasive bladder cancer arising in the bladder: a case report
Author's response to reviews Title: Concurrence of villous adenoma and non-muscle invasive bladder cancer arising in the bladder: a case report Authors: Yoichiro Kato (j2c789@bma.biglobe.ne.jp) Susumu
More informationFINALIZED SEER SINQ QUESTIONS
20150007 MP/H Rules/Histology: What is the proper histology code -- mucin producing adenocarcinoma or cholangiocarcinoma for the following case? See discussion. Discussion 4/10/13 Partial hepatectomy:
More information10/23/2012 CASE STUDIES: RENAL AND UROLOGIC IMPAIRMENTS. 1) Are there any clues from this history that suggest a particular diagnosis?
Case # 1 An underwriter enters your office, hands you a sheet of paper, and asks What do you think? Can we make an offer? You look at the paper and see it s lab results on a 60 year male looking for $500,000
More informationUrological Tumours 1 Kidney tumours 2 Bladder tumours
Urological Tumours 1 Kidney tumours 2 Bladder tumours Tim Bracey SpR Histopathology Derriford Hospital Kidney tumours What are we going to talk about?! Anatomy of urinary tract! Types of kidney tumours!
More informationBladder Cancer Guidelines
Bladder Cancer Guidelines Agreed by Urology CSG: October 2011 Review Date: September 2013 Bladder Cancer 1. Referral Guidelines The following patients should be considered as potentially having bladder
More informationDiagnosis and classification
Patient Information English 2 Diagnosis and classification The underlined terms are listed in the glossary. Signs and symptoms Blood in the urine is the most common symptom when a bladder tumour is present.
More informationSCOPE OF PRACTICE PGY-5
Recognize normal cytomorphology of cells derived from the respiratory, gastrointestinal, and genitourinary tracts, and body fluid (Cerebrospinal fluid, pleural and peritoneal fluid) Recognize normal cytomorphology
More informationControversies in the management of Non-muscle invasive bladder cancer
Controversies in the management of Non-muscle invasive bladder cancer Sia Daneshmand, MD Associate Professor of Urology (Clinical Scholar) Director of Urologic Oncology Director of Clinical Research Urologic
More informationDecember 22, Earl Berman, MD Attn Medical Review Two Vantage Way Nashville, TN
December 22, 2016 Earl Berman, MD Attn Medical Review Two Vantage Way Nashville, TN 37228 cmd.inquiry@cgsadmin.com Re: Draft Local Coverage Determination - Bladder Tumor Markers (DL36975) Dear Dr. Berman:
More informationBladder Case 1 SURGICAL PATHOLOGY REPORT. Procedure: Cystoscopy, transurethral resection of bladder tumor (TURBT)
Bladder Case 1 February 17, 2007 Specimen (s) received: Bladder Tumor Pre-operative Diagnosis: Bladder Cancer Post operative Diagnosis: Bladder Cancer Procedure: Cystoscopy, transurethral resection of
More informationCitation International journal of urology (2. Right which has been published in final f
Title Novel constant-pressure irrigation of renal pelvic tumors after ipsila Nakamura, Kenji; Terada, Naoki; Sug Author(s) Toshinori; Matsui, Yoshiyuki; Imamu Kazutoshi; Kamba, Tomomi; Yoshimura Citation
More informationStaging and Grading Last Updated Friday, 14 November 2008
Staging and Grading Last Updated Friday, 14 November 2008 There is a staging graph below Blood in the urine is the most common indication that something is wrong. Often one will experience pain or difficulty
More informationUpdate on Bladder Cancer: What s New in the 2016 WHO Classification of Bladder Tumors and 8 th Edition of AJCC Staging Manual
Update on Bladder Cancer: What s New in the 2016 WHO Classification of Bladder Tumors and 8 th Edition of AJCC Staging Manual Rajal B. Shah, M.D. Director, Urologic Pathology SHAHR6@ccf.org @rajalbshah
More informationAward Top Quizzes For Residents
Award Top Quizzes For Residents Giovanni Negri, MD, Bolzano (Italy) Eva M. Wojcik MD, Department of Pathology, Loyola University, Chicago (USA) Esther D. Rossi MD, PhD, MIAC, Division of Anatomic Pathology
More informationPathology Driving Decisions
Pathology Driving Decisions Part I: Understanding Your Diagnosis and Your Treatment Options May 7, 2018 Presented by: Dr. Matthew Mossanen completed his college and medical school training at UCLA. He
More informationIndex. Surg Oncol Clin N Am 14 (2005) Note: Page numbers of article titles are in boldface type.
Surg Oncol Clin N Am 14 (2005) 433 439 Index Note: Page numbers of article titles are in boldface type. A Abdominosacral resection, of recurrent rectal cancer, 202 215 Ablative techniques, image-guided,
More informationNon Small Cell Lung Cancer Histopathology ד"ר יהודית זנדבנק
Non Small Cell Lung Cancer Histopathology ד"ר יהודית זנדבנק 26.06.09 Lecture outlines WHO histological classification Macro/Micro assessment Early diagnosis Minimal pathology Main subtypes SCC, AdCa, LCLC
More informationUpdates in Urologic Pathology WHO Made Those Changes?! Peyman Tavassoli Pathology Department BC Cancer Agency
Updates in Urologic Pathology WHO Made Those Changes?! Peyman Tavassoli Pathology Department BC Cancer Agency World Health Organization Available in Feb 2016 Frame work for reporting Major contributing
More informationEtiology and diagnosis of bladder cancer
Etiology and diagnosis of bladder cancer Introduction Incidence: the most common urothelial tumor, representing the 2 nd most common urological tumor in men (4 th in overall frequency) and the 1 st in
More informationUrinary Bladder, Ureter, and Renal Pelvis
Urinary Bladder, Ureter, and Renal Pelvis Protocol applies to all carcinomas of the urinary bladder, ureter, and renal pelvis. Protocol revision date: January 2005 Based on AJCC/UICC TNM, 6th edition Procedures
More informationBiliary Tract Malignancy-Cyto/FISH
Client Biliary Tract alignancy-cyto/fish Case Number NR-17-2614 A., Right hepatic, brushing (ThinPrep): Cytology: Negative for malignancy. Reactive biliary tract epithelium. Fluorescence in situ hybridization
More informationIssues in the Management of High Risk Superficial Bladder Cancer
Issues in the Management of High Risk Superficial Bladder Cancer MICHAEL A.S. JEWETT DIVISION OF UROLOGY, DEPARTMENT OF SURGICAL ONCOLOGY, PRINCESS MARGARET HOSPITAL & THE UNIVERSITY OF TORONTO 1 Carcinoma
More informationFrom Morphology to Molecular Pathology: A Practical Approach for Cytopathologists Part 1-Cytomorphology. Songlin Zhang, MD, PhD LSUHSC-Shreveport
From Morphology to Molecular Pathology: A Practical Approach for Cytopathologists Part 1-Cytomorphology Songlin Zhang, MD, PhD LSUHSC-Shreveport I have no Conflict of Interest. FNA on Lymphoproliferative
More informationQ&A. Fabulous Prizes. Collecting Cancer Data: Bladder, Renal Pelvis, and Ureter 5/2/13. NAACCR Webinar Series
Collecting Cancer Data Bladder & Renal Pelvis NAACCR 2012 2013 Webinar Series Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching
More informationPreface to the Second Edition
Preface to the Second Edition This second edition of Diagnosis of Endometrial Biopsies and Curettings: A Practical Approach follows a number of favorable comments we received about the first edition. As
More informationACCME/Disclosures. Case History 4/13/2016. USCAP GU Specialty Conference Case 3. Ann Arbor, MI
USCAP GU Specialty Conference Case 3 March 2016 L. Priya Kunju, M.D. University of Michigan Health System Ann Arbor, MI University of Michigan Health System ACCME/Disclosures The USCAP requires that anyone
More information비뇨병리연구회공청회 조남훈 연세대학교병리학교실
비뇨병리연구회공청회 조남훈 연세대학교병리학교실 종양분류코드 - 방광암 표재성방광암 근층비침윤암 (Ta, Tis/ T1) 종양분류코드 진단서 ICD vs. ICO 사보험지급기준 중증질환분류 암등록사업 공보험 80-90% 지급기준 0 기암 -pta, ptis 특이한유형 면역 / 항암치료필요 재발과병기진행 다발성여부 진단확정주체 병리진단서 임상소견서 의무기록사 종양분류코드의변천사
More informationRenal tumors of adults
Renal tumors of adults Urinary Tract Tumors 2%-3% of all cancers in adults. The most common malignant tumor of the kidney is renal cell carcinoma. Tumors of the lower urinary tract are twice as common
More informationManagement of High Grade, T1 Bladder Cancer Douglas S. Scherr, M.D.
Management of High Grade, T1 Bladder Cancer Douglas S. Scherr, M.D. Assistant Professor of Urology Clinical Director, Urologic Oncology Weill Medical College-Cornell University Estimated new cancer cases.
More informationPatient identifiers Date of request Accession/Laboratory number. TUMOUR FOCALITY (Note 4) (Note 3)
Carcinoma of the Bladder Histopathology Reporting Guide Cystectomy, Cystoprostatectomy and Diverticulectomy Specimen Family/Last name Given name(s) Date of birth DD MM YYYY Patient identifiers Date of
More informationProtocol. Urinary Tumor Markers for Bladder Cancer
Protocol Urinary Tumor Markers for Bladder Cancer (20407) Medical Benefit Effective Date: 01/01/13 Next Review Date: 09/18 Preauthorization No Review Dates: 03/12, 09/12, 09/13, 09/14, 09/15, 09/16, 09/17
More informationRelated Policies None
Medical Policy MP 2.04.07 BCBSA Ref. Policy: 2.04.07 Last Review: 06/22/2017 Effective Date: 06/22/2017 Section: Medicine End Date: 09/27/2018 Related Policies None DISCLAIMER Our medical policies are
More informationBladder Cancer Canada November 21st, Bladder Cancer 2018: A brighter light at the end of the cystoscope
Bladder Cancer Canada November 21st, 2018 Bladder Cancer 2018: A brighter light at the end of the cystoscope Chris Morash MD FRCSC Associate Professor, University of Ottawa Head, Urological Oncology Bladder
More informationOriginal Policy Date
MP 2.04.05 Urinary Tumor Markers for Bladder Cancer Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature search/12:2013 Return to
More informationImmunohistochemistry and Bladder Tumours
Immunohistochemistry and Bladder Tumours Dr. Andrew J. Evans MD PhD FRCPC Consultant in Genitourinary Pathology University Health Network Toronto, ON Objec ves Review markers of urothelial differen a on
More informationEfficient and Effective Use of Exfoliative Markers
Innovations in Urologic Oncology: Bladder Cancer Efficient and Effective Use of Exfoliative Markers Jared M Whitson, MD April 9 th, 2010, CA URINARY TUMOR MARKERS Future Directions Urinary Tumor Markers
More informationManagement of Superficial Bladder Cancer Douglas S. Scherr, M.D.
Management of Superficial Bladder Cancer Douglas S. Scherr, M.D. Assistant Professor of Urology Clinical Director, Urologic Oncology Weill Medical College-Cornell University Estimated new cancer cases.
More informationMultiple Primary and Histology Site Specific Coding Rules URINARY. FLORIDA CANCER DATA SYSTEM MPH Urinary Site Specific Coding Rules
Multiple Primary and Histology Site Specific Coding Rules URINARY 1 Prerequisites 2 Completion of Multiple Primary and Histology General Coding Rules 3 There are many ways to view the Multiple l Primary/Histology
More informationA215- Urinary bladder cancer tissues
A215- Urinary bladder cancer tissues (formalin fixed) For research use only Specifications: No. of cases: 45 Tissue type: Urinary bladder cancer tissues No. of spots: 2 spots from each cancer case (90
More informationTransitional Cell Carcinoma of the Renal Pelvis The Diagnostic Role of Pelvic Washings
Anatomic Pathology / TRANSITIONAL CELL CARCINOMA OF THE RENAL PELVIS Transitional Cell Carcinoma of the Renal Pelvis The Diagnostic Role of Pelvic Washings Deborah Witte, MD, Luan D. Truong, MD, and Ibrahim
More informationClinical significance of immediate urine cytology after transurethral resection of bladder tumor in patients with non-muscle invasive bladder cancer
International Journal of Urology (2011) 18, 439 443 doi: 10.1111/j.1442-2042.2011.02766.x Original Article: Clinical Investigationiju_2766 439..443 Clinical significance of immediate urine cytology after
More informationBladder Cancer Early Detection, Diagnosis, and Staging
Bladder Cancer Early Detection, Diagnosis, and Staging Detection and Diagnosis Catching cancer early often allows for more treatment options. Some early cancers may have signs and symptoms that can be
More informationBLADDER TUMOURS A REVIEW OF 150 PATIENTS TREATED AT THE INSTITUTE OF UROLOGY AND NEPHROLOGY GENERAL HOSPITAL KUALA LUMPUR
Med. J. Malaysia Vol. 38. No. I March 1983. BLADDER TUMOURS A REVIEW OF 150 PATIENTS TREATED AT THE INSTITUTE OF UROLOGY AND NEPHROLOGY GENERAL HOSPITAL KUALA LUMPUR ZAKRIYA MAHAMOOTH HUSSAIN AWANG SUMMARY
More informationPathology of bladder cancer in Egypt; a current study.
Pathology of bladder cancer in Egypt; a current study. Thesis Submitted for partial fulfillment of Master degree in urology By Mohamed Atef Mohamed Ahmed M.B.B.CH Supervised by Prof.Dr.: Omar Mohamed Abdel-
More informationCytology and Surgical Pathology of Gynecologic Neoplasms
Cytology and Surgical Pathology of Gynecologic Neoplasms Current Clinical Pathology ANTONIO GIORDANO, MD, PHD SERIES EDITOR For further titles published in this series, go to http://www.springer.com/springer/series/7632
More informationAppendix 4: WHO Classification of Tumours of the pancreas 17
S3.01 The WHO histological tumour type must be recorded. CS3.01a The histological type of the tumour should be recorded based on the current WHO classification 17 (refer to Appendices 4-7). Appendix 4:
More informationCan Use the NMP22 BladderChek Decrease the Frequency of Cystoscopy in the Follow up of Patients with Bladder Carcinoma?
Original Article Int J Nephrol Urol, 2009; 1(1):51-55 Can Use the NMP22 BladderChek Decrease the Frequency of Cystoscopy in the Follow up of Patients with Bladder Carcinoma? Adel Allam 1*, Badawi Hathout
More informationPAP SMEAR by Dr.Shantha Krishnamurthy MD Senior Consultant Pathology Fortis Hospitals
PAP SMEAR by Dr.Shantha Krishnamurthy MD Senior Consultant Pathology Fortis Hospitals Historical Named after George Papanicolaou, a Greek American Studied cervical epithelium in menstrual cycle of guinea
More informationICUD-EAU International Consultation on Bladder Cancer 2012: Pathology
EUROPEAN UROLOGY 63 (2013) 16 35 available at www.sciencedirect.com journal homepage: www.europeanurology.com Review Bladder Cancer ICUD-EAU International Consultation on Bladder Cancer 2012: Pathology
More informationHistological Typing Of Cancer And Precancer Of The Oral Mucosa
Histological Typing Of Cancer And Precancer Of The Oral Mucosa 1 / 7 2 / 7 3 / 7 Histological Typing Of Cancer And Within the last decade, histologic grading has become widely accepted as a powerful indicator
More informationHow Many Diseases in Carcinoma in situ?
How Many Diseases in Carcinoma in situ? Eva Compérat La Pitié Salpêtrière Assistance Publique Université Pierre et Marie Curie, Paris VI Carcinogenesis of Bladder Cancer (BC) BC is a panurothelial disease
More informationGlossary of Terms Primary Urethral Cancer
Patient Information English Glossary of Terms Primary Urethral Cancer Advanced cancer A tumour that grows into deeper layers of tissue, adjacent organs, or surrounding muscles. Anaesthesia (general, spinal,
More informationSynonyms. Nephrogenic metaplasia Mesonephric adenoma
Nephrogenic Adenoma Synonyms Nephrogenic metaplasia Mesonephric adenoma Definition Benign epithelial lesion of urinary tract with tubular, glandular, papillary growth pattern Most frequently in the urinary
More informationThe 2015 World Health Organization Classification for Lung Adenocarcinomas: A Practical Approach
The 2015 World Health Organization Classification for Lung Adenocarcinomas: A Practical Approach Dr. Carol Farver Director, Pulmonary Pathology Pathology and Laboratory Medicine Institute Objectives Discuss
More information2004 World Health Organization Classification of the Noninvasive Urothelial Neoplasms: Inherent Problems and Clinical Reflections
european urology supplements 8 (2009) 453 457 available at www.sciencedirect.com journal homepage: www.europeanurology.com 2004 World Health Organization Classification of the Noninvasive Urothelial Neoplasms:
More information2016 myresearch Science Internship Program: Laboratory Medicine. Civic Education Office of Government and Community Relations
2016 myresearch Science Internship Program: Laboratory Medicine Civic Education Office of Government and Community Relations Aliya Ansari Science Internship Program: Laboratory Medicine Cytologic Differentiation
More informationBladder Cancer Diagnostic Tests
ISSN (Online): 1694-0784 ISSN (Print): 1694-0814 18 Bladder Cancer Diagstic Tests Shefali Jasra,Rishi Gupta, Shruti Mittal Lingayas Institute of Techlogy and Management Lingayas Institute of Techlogy and
More informationReviewing Immunotherapy for Bladder Carcinoma In Situ
Reviewing Immunotherapy for Bladder Carcinoma In Situ Samir Bidnur Dept of Urologic Sciences, Grand Rounds March 1 st, 2017 Checkpoint Inhibition and Bladder Cancer, an evolving story with immunotherapy
More information57th Annual HSCP Spring Symposium 4/16/2016
An Unusual Malignant Spindle Cell Lesion to Involve the Breast Erinn Downs-Kelly, D.O. Associate Professor of Pathology University of Utah & ARUP Laboratories No disclosures Case 39 y/o female with no
More information4/12/2018. MUSC Pathology Symposium Kiawah Island April 18, Jesse K. McKenney, MD
MUSC Pathology Symposium Kiawah Island April 18, 2018 Jesse K. McKenney, MD 1 Urothelial Carcinoma with Alternative Differentiation 2 Urothelial Carcinoma with Alternative Differentiation Recognition as
More informationCK20 and p53 Immunohistochemical Staining Patterns in Urinary Bladder Specimens With Equivocal Atypia. Correlation With Outcomes
CK20 and p53 Immunohistochemical Staining Patterns in Urinary Bladder Specimens With Equivocal Atypia Correlation With Outcomes Javier A. Arias-Stella III, MD; Alpa B. Shah, MD, MPH; Nilesh S. Gupta, MD;
More information